{"id":"agn-199201-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Iris pigmentation changes"},{"rate":null,"effect":"Eyelash growth"},{"rate":null,"effect":"Eye irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The drug binds to FP receptors in the eye, enhancing drainage of aqueous humor through the uveoscleral (unconventional) pathway. This mechanism reduces intraocular pressure, which is the primary pathogenic factor in glaucoma and ocular hypertension. Prostaglandin analogs are a well-established drug class for glaucoma management.","oneSentence":"AGN-199201 is a selective prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:21:16.361Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma or ocular hypertension (Phase 2)"}]},"trialDetails":[{"nctId":"NCT02595528","phase":"PHASE2","title":"A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-04-29","conditions":"Presbyopia","enrollment":163},{"nctId":"NCT02780115","phase":"PHASE2","title":"A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-05-26","conditions":"Presbyopia","enrollment":151},{"nctId":"NCT02197806","phase":"PHASE2","title":"Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-07","conditions":"Presbyopia","enrollment":65}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1907,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AGN-199201 ophthalmic solution","genericName":"AGN-199201 ophthalmic solution","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AGN-199201 is a selective prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure. Used for Glaucoma or ocular hypertension (Phase 2).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}